Breast Cancer Clinical Trial

Targeted Intra-Operative Radiotherapy for the Management of Ductal Carcinoma In-Situ of the Breast

Summary

We hypothesize that the combination of mammography and CE-MRI will improve the surgeon and radiologist's ability to define extent of disease prior to surgical resection, improve the odds of obtaining clear surgical margins, and increase the efficacy of IORT delivered immediately after initial surgical resection. In this investigation, we will determine whether or not patients deemed eligible for 'immediate" IORT based on mammography and CE-MRI can be successfully treated without the need for re-excision or additional radiotherapy due to inadequate surgical margins.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patients with biopsy-proven DCIS, mammographic and CE-MRI evidence of DCIS measuring great then equal to 4cm, and a desire to receive breast conserving therapy, will be considered for participation in this study.
Patient history, physical examination findings, and demographics (sex, age, height, weight, bra size, etc.) will be performed and documented.

Inclusion Criteria for Initial Registration (all patients cohorts):

All cohorts

Signed informed consent and HIPAA documents
Female sex
Age great then equal to 40 years
Localized ductal carcinoma in situ
Clinically and/or histologically negative axillary lymph nodes
No imaging or clinical findings suggestive of invasive carcinoma.

Cohort 1 (Immediate IORT group)

Localized DCIS measuring less then equal to 4 cm on preoperative imaging.
Cohort 2 (Delayed IORT group)
Localized DCIS measuring less then equal to4 cm or less on surgical pathology
Delayed IORT could be performed for the explicit purpose of administering IORT or performed following re-excision of a previously operated breast to achieve clear surgical margins.
This cohort includes patients who were excluded from immediate IORT based on pre-operative imaging suggesting ineligibility for immediate IORT, but who are subsequently found to meet histological criteria (localized DCIS less then equal to 4 cm and no invasive cancer) for IORT based on surgical pathology.
Unifocal microinvasive (T1mic or invasive focus less then equal to 1mm in maximal diameter) is allowed following initial WLE if surgical pathology margins were less then equal to2 mm for both the invasive and non-invasive components.
Delayed IORT must be performed within 3 months of initial WLE.
Cohort 3 Subjects who received IORT at the time of initial WLE but whose surgical pathology showed them to be unsuitable candidates for IORT alone on the basis of:
DCIS measuring greater than 5 cm on surgical pathology.
T1a (less than 1 mm) or larger invasive carcinoma associated with extensive DCIS.
Surgical margins width less than1 mm.

Exclusion Criteria:

Male sex
Age less than 40
DCIS associated with any evidence of microinvasion or invasive carcinoma on pre-operative imaging or core biopsy of the breast or axillary nodes.
DCIS that is multicentric in the ipsilateral breast. Multicentricity will be defined at 2 or more lesions separated by more than 3 cm in the same breast.
Non-epithelial breast malignancies such as sarcoma or lymphoma
DCIS associated with diffuse suspicious or indeterminate microcalcifications
Pregnancy or lactation
Collagen vascular diseases, including Systemic lupus erythematosus, Systemic sclerosis (scleroderma), CREST Syndrome (calcinosis, Raynaud phenomenon, esophageal dysfunction, sclerodactyly, telangiectasia, and the presence of anticentromere antibodies), polymyositis, dermatomyositis with a CPK level above normal or with an active skin rash, inclusion-body myositis, or amyloidosis
Serious psychiatric or addictive disorders

Study is for people with:

Breast Cancer

Estimated Enrollment:

22

Study ID:

NCT00556907

Recruitment Status:

Terminated

Sponsor:

University of Southern California

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

USC/Norris Comprehensive Cancer Center
Los Angeles California, 90033, United States

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Estimated Enrollment:

22

Study ID:

NCT00556907

Recruitment Status:

Terminated

Sponsor:


University of Southern California

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider